37 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
3. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
4. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
5. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
6. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
7. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
8. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
9. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
10. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
11. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
12. Circulating Activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia
13. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?
14. P-065. New human models of preeclampsia; offering physiologically relevant assays for the development of therapeutics to ameliorate preeclamptic vascular dysfunction
15. P-009. Associations between circulating sFlt-1 and PlGF and preeclampsia with severe maternal complications, or eclampsia
16. O-004. Circulating SIGLEC6 is deranged in preeclampsia and may be a biomarker of disease severity
17. Peptides do not prevent cleavage of endoglin to produce soluble endoglin
18. 4 Epidermal growth factor receptor positively regulates sFlt1 secretion
19. 43 New generation antiplatelet therapies to prevent preeclampsia
20. 286. Endothelin-1 is elevated prior to the development of term preeclampsia and is exacerbated in established severe early onset preeclampsia
21. 200. Clinical trial of metformin to treat preterm preeclampsia: pharmacokinetics and biomarker studies
22. 190. Combination sulfasalazine and metformin are additive in reducing placental secretion of antiangiogenic factor sFlt
23. 82. Disulfiram inhibits placental sFLT-1 secretion
24. 291. MicroRNAs in maternal circulation as predictors of preeclampsia at term
25. 293. Preclinical assessment of new generation antiplatelet therapies to prevent preeclampsia
26. 296. Loss of Placental NR4A2 may contribute to the pathogeneisis of pre-eclampsia
27. 131. EGFR and the mitochondria; two parallel pathways regulating sFLT-1 secretion from placenta
28. [273-POS]
29. [28-OR]
30. [261-POS]
31. [44-OR]
32. [6-OR]
33. [44-OR]: Statins reduce soluble Flt1, and quench endothelial dysfunction in primary human tissues, but increase soluble endoglin release
34. [28-OR]: The newly described primate and placental specific sFlt1 isoform – e15a is biologically active and antagonises VEGF
35. [6-OR]: Proton pump inhibitors for treatment of preeclampsia
36. [273-POS]: Sulfasalazine reduces the toxins of preeclampsia soluble Flt1 and soluble endoglin and quenches endothelial dysfunction in primary human tissues: A novel potential therapeutic
37. [261-POS]: Heme oxygenase-1 is not reduced in pre-eclampsia and does not regulate sFlt-1 or soluble endoglin production
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.